ASH | BCMA-CD3双特异性抗体治疗多发性骨髓瘤临床数据积极(2)
2020-06-01 未知 admin
[2] Safety and Preliminary Clinical Activity of REGN5458, an Anti-BCMA x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Retrieved December 9, 2019, from https://investor.regeneron.com/static-files/67055c32-348a-4851-b6e6-b03c535af879
原标题:ASH | 再生元BCMA-CD3双特异性抗体临床数据积极,治疗多发性骨髓瘤
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。▽关注【药明康德】微信公众号
鐑瘝锛